Astrana Health (NASDAQ:ASTH) Given New $50.00 Price Target at BTIG Research

Astrana Health (NASDAQ:ASTH) had its target price lifted by BTIG Research from $40.00 to $50.00 in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

ASTH has been the topic of a number of other reports. Weiss Ratings raised shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Zacks Research raised shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 11th. Truist Financial increased their price objective on shares of Astrana Health from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Robert W. Baird increased their price objective on shares of Astrana Health from $37.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.86.

Astrana Health Stock Up 8.9%

Shares of NASDAQ ASTH opened at $39.30 on Friday. The firm’s 50-day moving average price is $27.38 and its 200-day moving average price is $25.67. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of 64.43 and a beta of 0.98. Astrana Health has a 12-month low of $18.08 and a 12-month high of $39.90.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.45. Astrana Health had a net margin of 0.86% and a return on equity of 9.31%. The firm had revenue of $965.10 million for the quarter, compared to analysts’ expectations of $949.21 million. During the same period in the prior year, the company earned $0.42 EPS. The business’s revenue was up 55.6% compared to the same quarter last year. On average, equities research analysts anticipate that Astrana Health will post 1.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds have recently added to or reduced their stakes in ASTH. Royal Bank of Canada grew its stake in Astrana Health by 6.5% in the 1st quarter. Royal Bank of Canada now owns 278,619 shares of the company’s stock worth $8,640,000 after acquiring an additional 17,028 shares in the last quarter. AQR Capital Management LLC bought a new position in Astrana Health in the 1st quarter worth about $933,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Astrana Health by 5.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after acquiring an additional 1,263 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Astrana Health by 4,365.2% in the 1st quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company’s stock worth $346,000 after acquiring an additional 10,913 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in Astrana Health by 5.8% in the 1st quarter. Intech Investment Management LLC now owns 44,586 shares of the company’s stock worth $1,383,000 after acquiring an additional 2,462 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors.

Trending Headlines about Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Astrana Health beat first-quarter sales expectations, reporting revenue of $965.1 million versus the $949.2 million consensus, while EPS came in at $0.74, well above the $0.29 estimate. Revenue also rose 55.6% year over year, signaling strong operating momentum. Article title
• Positive Sentiment: The company’s full-year 2026 revenue guidance of $3.8 billion to $4.1 billion was issued near Wall Street expectations, which can support confidence that growth remains intact. Article title
• Positive Sentiment: Needham & Company raised its price target on ASTH to $41 from $30 and kept a buy rating, while BTIG Research lifted its target to $50 from $40 and also reiterated a buy rating. Those moves suggest analysts see more upside after the earnings beat.
• Neutral Sentiment: Investors are also digesting the earnings call transcript and presentation, which may provide additional detail on margins, guidance, and the company’s growth strategy.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.